Onkológia 3/2022

First-line treatment of metastatic castration-sensitive prostate cancer

The article is an overview of the studies´ results, which have already been transferred or probably will be transformed into guidelines for the first-line treatment of men with metastatic castration-sensitive prostate cancer (CSPC) in near future. The first part focuses on clinical significance of the docetaxel addition to the previous standard of treatment, which was surgical or chemical castration. The following section is devoted to the significant contribution of new endocrine agents (abiraterone-acetate, apalutamide, darolutamide, and enzalutamide) with androgen deprivation therapy (ADT) compared to ADT alone. However, there are growing data on the positive effect of the triplets consisted of ADT with docetaxel and an inhibitor of androgen synthesis or novel antiandrogens for survival of patients with metastatic CSPC.

Keywords: Prostate cancer. Sensitivity to castration. Metastatic disease. Docetaxel. Hormonal agents.